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Abstract
Typing of human enterovirus (EV) remains a major goal for diagnostic and epidemiological purposes. Whereas sequencing of the VP1 coding
region is the reference standard for EV typing, a method relying on sequencing of the VP2 coding region has been proposed as an alternative;
however, this has been validated only on cell culture supernatants. To avoid the selection of cultivable strains and to quicken the
identiﬁcation step, a new semi-nested PCR method targeting the VP2 region was developed by use of the CODEHOP strategy. After
validation of the method on reference and clinical strains, a total of 352 clinical specimens found to be positive for EV RNA (138 with the
GeneXpert EV kit and 214 with the Enterovirus R-gene kit) during a 3-year period (2010–2012) were analysed prospectively for VP2
genotyping. Overall, 204 (58%) specimens were typeable. A higher proportion of throat swab/stool specimens than of cerebrospinal ﬂuid
(CSF) specimens was found to be typeable (94 of 142 (66.2%) vs. 83 of 169 (49.1%), respectively, p <0.01 by the chi-square test). Moreover,
the median Ct value obtained was lower for typeable specimens than for untypeable specimens (32.20 vs. 33.01, p <0.05, and 25.96 vs. 31.74,
p <0.001, for the GeneXpert and R-gene tests, respectively, by the Mann–Whitney–Wilcoxon test). These results suggest that, in cases of
EV meningitis, a peripheral specimen (i.e. throat swab or stool) that is susceptible to exhibiting a higher viral load should be used in
preference to CSF for identifying the causative EV genotype by use of the VP2 typing method without cell culture isolation.
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Introduction
Human enteroviruses (EVs) are small, non-enveloped viruses
belonging to the Enterovirus genus of the Picornaviridae family.
The EV genome consists of a single-stranded linear RNA
molecule of approximately 7500 nucleotides with one open
reading frame ﬂanked by two 5′ and 3′ non-coding regions
(NCs) [1]. The open reading frame encodes a polyprotein that
is subsequently cleaved into structural proteins (VP4, VP2,
VP3, and VP1) that are assembled to form the viral capsid, and
non-structural proteins that are implicated in virus replication
and maturation.
EVs are mainly transmitted via the faecal–oral route,
but also by droplets from the upper respiratory tract, and
are responsible for many human infections, with a broad
range of clinical manifestations; most of them are asymp-
tomatic or mild, but some can lead to severe presenta-
tions, especially in neonates and immunocompromised
patients. Certain EV infections are considered to be
emerging, as exempliﬁed by the severe epidemics in Asia
with EV-A71 [2].
Originally subdivided on the basis of antigenic properties
and according to their natural and experimental pathogenesis,
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human EVs are currently classiﬁed as four species (EV-A to
EV-D), with species C including the three poliovirus (PV)
serotypes [3,4]. More than 100 genotypes have been
reported to date, and new ones are regularly described
(http://www.picornaviridae.com). There are many reasons for
typing EV strains in clinical or environmental specimens,
including: (i) rapid identiﬁcation of strains with high clinical
relevance (i.e. PV in countries where PV infection is not still
eradicated or EV-A71 strains are related to encephalitis); (ii)
epidemiological and clinical monitoring of EV circulation in
humans; (iii) epidemiological surveillance of EV circulation in
the environment; and (iv) identiﬁcation of new genotypes and
variants [5].
The reference standard for typing of strains is currently
analysis of the VP1 gene; alternative methods targeting the
VP2 or VP4 capsid proteins have also been described [5].
However, a unique set of primers is hardly sufﬁcient for
amplifying all EV types, and the use of degenerate primers
with high inosine content carries the risk of non-speciﬁc
ampliﬁcation [6–8]. Importantly, almost all of these methods
have been used for typing HEV strains isolated in cell culture;
few of them have succeeded in amplifying EV sequences
directly from clinical samples, preventing selection by cell
culture.
These pitfalls led some authors to propose a two-step
strategy involving the use of speciﬁc primers targeting one
group of EVs [9–13]. Alternatively, an original primer design
has been proposed for the ampliﬁcation and identiﬁcation of
new genes sharing homologies with previously described
sequences [8]. This strategy, named CODEHOP for COnsen-
sus-DEgenerate Hybrid Oligonucleotide Primers, led to the
description of new viruses, including herpesvirus types, by
targeting the conserved DNA polymerase gene [14] and
papillomavirus types by amplifying homologue genes in the L1
protein-coding region [15]. This original strategy has been
proposed for EV typing by adaptation of the primers most
commonly used for targeting of the VP1 region [16] with a
CODEHOP design [6].
The aim of this study was to adapt the primers targeting the
VP2 region, which was shown to be useful in EV typing [17],
according to the CODEHOP design; an increase in sensitivity
of the test could allow EV typing directly in clinical specimens
without previous isolation by cell culture. After validation with
dilutions of cell culture supernatants, the new method was
tested prospectively on 352 clinical specimens that were found
to be positive for EV over a 3-year period in Saint-Etienne,
France. Overall, 58% of the specimens were typed successfully.
Huge differences were observed according to the origin of
clinical specimens and to the level of the viral load, suggesting
that peripheral specimens are more suitable than cerebrospi-
nal ﬂuid (CSF) specimens for direct typing of EV in clinical
practice.
Materials and Methods
Viral strains and analytical sensitivity analysis
For the reference and clinical strains used for the development
of the technique, virus titration was performed according to
the Reed and Muench method, and titres were expressed as
50% tissue culture infective dose (TCID50)/50 lL. Virus stocks
were ten-fold serially diluted in phosphate-buffered saline
before RNA extraction; the results were recorded as the
lowest detectable log10 dilution and the corresponding con-
centration.
Clinical specimens
A total of 352 consecutive specimens (169 CSFs, 107 throat
swabs, 35 stools, 19 respiratory secretions, 17 blood speci-
mens, and ﬁve cutaneous swabs) taken from patients showing
EV infection at the University Hospital of Saint-Etienne,
France, over a 3-year period (2010–2012) and found to be
positive for EV RNA in the 5′NC region on a routine basis,
were included prospectively for typing analysis. A point-of-
care strategy with the Xpert EV kit (Cepheid Europe,
Maurens-Scopont, France) detected 138 positive CSF spec-
imens, and all of the other specimens tested positive with
the Enterovirus R-gene kit (bioMerieux, Marcy l’Etoile,
France).
RNA extraction
Viral RNA was extracted from 200 lL of cell culture
supernatant or clinical specimen with the NUCLISENS easy-
MAG instrument (bioMerieux). The speciﬁc B protocol was
used according to the manufacturer’s recommendations, and
nucleic acids were eluted in 50 lL.
Ampliﬁcation experiments
All experiments were performed with the general precautions
and conditions previously described [17].
5′NC region. For CSF specimens, EV RNA was detected with
either the Xpert EV kit on the GeneXpert instrument
(Cepheid) in cases of emergency, or with the Enterovirus
R-gene kit on the ABI PRISM 7500 system (Applied Biosys-
tems, Courtaboeuf, France) in routine use, both tests being
commercial one-step reverse transcription and real-time PCR
assays. For other clinical specimens, the EV genome was
detected with the R-gene kit. The analytical sensitivity was
evaluated on reference strains to 0.0002–200 TCID50/mL for
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GeneXpert [18] and 0.002–245 TCID50/50 lL for R-gene
[19].
VP1 region. The reagent and ampliﬁcation conditions were
those published previously [6].
VP2 region. Ten microlitres of extracted RNA was reverse
transcribed into cDNA at 42°C for 45 min with 200 units
of SuperScriptIII reverse transcriptase (Invitrogen, Cergy
Pontoise, France), 2.5 ng/lL random primers (Invitrogen),
and 10 units of RnaseOUT recombinant RNase inhibitor
(Invitrogen). A ﬁrst ampliﬁcation step was performed by using
two pairs of sense (AM11 and AM12) and antisense (AM31 and
AM32) primers as previously described [17], in order to obtain
a fragment of 584 bp. For the classic VP2 method, the second
ampliﬁcation was performed as previously described [17].
CODEHOP PCR was performed with 2 lL of the ﬁrst
PCR product, 1.25 units of HotStar Taq DNA polymerase
(Qiagen, Courtaboeuf, France), 40 pmol of primers NS20
(TCCAAGGGCTGGTGGTGGAARYTNCC) and NS30 (TTR
TTGGTCCGCAGGTTGATCMWYTGRTGNGG) and 3 mM
MgCl2 in a ﬁnal volume of 50 lL. The Taq polymerase was
activated by incubation at 95°C for 15 min prior to 30
ampliﬁcation cycles of 95°C for 30 s, 65°C for 45 s, and 72°C
for 45 s. The expected size of the amplicon was 379 bp (with
reference to PV-1; GenBank accession number V01149).
Template puriﬁcation and sequencing
The amplicons were puriﬁed with the High Pure PCR Product
Puriﬁcation Kit (Roche Diagnostics, Meylan, France) or a
QIAquick gel extraction kit (Qiagen), depending on the
presence of single or multiple bands, respectively. The puriﬁed
products were sequenced according to the Sanger method,
with the GenomeLab Dye Terminator Cycle Sequencing Quick
Start kit (Beckman Coulter, Villepinte, France), as previously
described [17]. The sequencing primers were NS20/NS30 and
AN89/AN88 [6] for the VP2 region and the VP1 region,
respectively. After puriﬁcation of the amplicons with the
Dye-Terminator Ex 2.0 kit (Qiagen), the electrophoresis and
analysis of DNA sequence reactions were performed with the
CEQ8000 automated DNA sequencer (Beckman Coulter).
Sequence analysis and phylogeny
To determine the EV type, the sequences were compared with
all of the corresponding EV sequences available in the GenBank
database for the VP2 region by the use of BLAST software
[20]. By analogy with VP1 [21], and as previously described
[17], nucleotide sequence homology of at least 75% was
required for assignment to the same genotype. Sequence
alignments were performed with the ClustalW2 program [22].
Statistical analysis
Chi-quare and Mann–Whitney–Wilcoxon tests were per-
formed with SPSS software version 20.0 (IBM, Chicago, IL,
USA). A p-value of <0.05 was considered to be statistically
signiﬁcant.
Results
Technical validation of the CODEHOP VP2 typing method
CODEHOP primers (NS20 and NS30) were deﬁned in a
conserved region of the VP2 protein previously selected for its
pertinence for EV typing [17]. Each of these new primers was
designed according to the CODEHOP strategy [8,14] by use of
the computer algorithm available at http://blocks.fhcrc.org. The
5′ non-degenerate end of 15 bases for both primers corre-
sponded to the 5′ consensus clamp, i.e. the most probable
nucleotide predicted for each ﬂanking codon; the 3′ degener-
ate core of 11 bases and 17 bases for NS20 and NS30,
respectively, encoded highly conserved amino acids (see
Fig. 1a,b for primer NS20).
In order to validate the CODEHOP semi-nested protocol,
different parameters, including annealing temperature,
amount of primers, and MgCl2 concentration, were tested
for the development of a sensitive molecular technique. With
the optimal conditions reported in the previous section, the
new semi-nested PCR was shown to be more sensitive and
to show fewer adventitious bands than the initial version of
the VP2 test with conventional primers [17] for ﬁve
reference strains belonging to the four different human EV
species (Fig. 1c).
The ability of the primers to match the 95 genotypes of EV
for which the VP2 gene sequence is available was tested by
nucleotide sequence alignment; no major mismatch was
observed for any of the primers used (sense and antisense
primers for ﬁrst and nested PCR assays) (data not shown). In
addition, the sensitivity of the new method was compared with
those of the EV R-gene kit targeting the 5′NC region and of
the VP1 method on ten-fold serial dilutions of 14 EV reference
or clinical strains (Table 1). Both typing methods were less
sensitive than the R-gene test, with the exception of the
CV-A21 strain, for which the VP2 method was 1 log10 more
sensitive. The VP2 method was more sensitive than or as
sensitive as the VP1 method for, respectively, six (CV-A9, E-4,
E-11, E-30, CV-A21, and EV-D70) and seven (CV-A16, EV-A71,
E-17, CV-B3, CV-A24, PV-2, and PV-3) strains; it was 1 log10
less sensitive than the VP1 method for PV-1.
A preliminary study was performed on 98 clinical specimens
found to be positive for EV in 2010 to control the accuracy of
the VP2 test by comparison with the reference VP1 CODE-
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HOP method [6]. Overall, 35, 29 and 34 specimens were
shown to be typeable with both methods, typeable with only
one method, or untypeable, respectively. The 35 specimens
that were typeable with both methods showed the same
genotype in all cases (one CV-A4, one CV-A6, one CV-A10,
seven CV-B2, two CV-B5, 11 E-6, four E-11, one E-16, one
E-18, four E-30, and two EV-D68). The agreement between the
typing methods was 70.4% (p <0.001, Cohen kappa coefﬁcient
of 0.41, 95% CI 0.23–0.59). The sensitivities of the typing
methods were very similar (48.0% and 53.1% for VP1 and VP2,
respectively; not signiﬁcant by the chi-square test).
Prospective evaluation of the CODEHOP VP2 typing method
over a period of 3 years
A panel of 352 consecutive clinical specimens found to be
positive for the EV genome over a period of 3 years (2010–
2012) with two different commercial detection kits was used
for evaluation of the VP2 method. Overall, 204 clinical
specimens were shown to be typeable (58.0%); for the
assigned type, all of them showed high nucleic acid homology
(>75%) with at least one of the corresponding sequences
available in GenBank by BLAST alignment. The detailed results
are shown in Table 2 (distribution of specimens by year and by
TABLE 1. Analytical sensitivity of the new VP2 typing method in comparison with that of the Enterovirus R-gene kit and of the
VP1 typing method
Species Serotypes Strain
Titre
(TCID50/50 lL)
Lowest detectable titre (TCID50/50 lL)
Detection by
targeting the 5′NC
region (R-gene assay)
Genotyping by
targeting the VP1
region [6]
Genotyping by
targeting the
VP2 region
HEV-A CV-A16 Reference G-10 106 102 101 101
EV-A71 Reference BrCr 105 102 101 101
HEV-B CV-A9 Clinical isolate SE-81-3363a 105 102 101 102
E-4 Clinical isolate (1980) 106 101 1 101
E-11 Clinical isolate SE-02-70530a 106 1 10 1
E-17 Clinical isolate SE-99-94960a 103 104 101 101
CV-B3 Clinical isolate (1995) 5 9 106 102 101 101
E-30 Reference Bastianni 5 9 104 103 102 103
HEV-C CV-A21 Reference Kuykendall 5 9 105 101 101 102
CV-A24 Reference Joseph 104 103 103 103
PV-1 Reference Sabin 106 101 1 10
PV-2 Reference Sabin 106 102 101 101
PV-3 Reference Sabin 5 9 106 102 1 1
HEV-D EV-D70 Reference J670/71 105 102 10 101
NC, non-coding region; TCID50, 50% tissue culture infectious dose.
aStrain previously characterized [17].
FIG. 1. Set-up of the CODEHOP VP2 typing method. (a) Design of the NS20 primer (the same strategy was used for NS30). After alignment of the
sequences of EV, including the newly described ones, the conserved blocks were determined according to http://blocks.fhcrc.org. The amino acid
block corresponding to the region previously used for the AM21 and AM22 primers was selected. The targeted sequence of the block is shown in a
red box. (b) Design of the NS20 primer. The most frequent amino acid was selected in each position of the block, and the nucleotide sequence was
designed with a 5′ consensus clamp and a 3′ degenerate core according to the CODEHOP strategy. (c) Electrophoregrams of ampliﬁcation products
of a variety of enterovirus strains belonging to different species after use of either the initial version (left-side panels) of the VP2 typing method
described in [17], or the CODEHOP version of this test (right-side panels). The strains used are those listed in Table 1 at the same multiplicity of
infection.
TABLE 2. Efﬁcacy of typing of the VP2 typing method on 352 clinical specimens recovered between 2010 and 2012
Origin (5′NC detection
method used)
Year
Total2010 2011 2012
Typed (%) Total Typed (%) Total Typed (%) Total Typed (%) Total
CSF (GeneXpert) 14 (37.8) 37 32 (45.7) 70 21 (67.7) 31 67 (48.6) 138
CSF (R-gene) 6 (54.5) 11 7 (41.2) 17 3 (100) 3 16 (51.6) 31
Throat (R-gene) 21 (61.8) 34 29 (65.9) 44 19 (65.5) 29 69 (64.5) 107
Stools (R-gene) 3 (75.0) 4 8 (72.7) 11 14 (70.0) 20 25 (71.4) 35
Othera (R-gene) 8 (66.7) 12 8 (57.1) 14 11 (73.3) 15 27 (65.8) 41
Total 52 (53.1) 98 84 (53.8) 156 68 (69.4) 98 204 (58.0) 352
CSF, cerebrospinal ﬂuid; NC, non-coding region.
aBlood, respiratory samples, and cutaneous swabs.
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origin of specimen) and Table 3 (list of EV genotypes by year of
recovery). With regard to specimen origin, a higher propor-
tion of throat/stool specimens than of CSF specimens was
found to be typeable (94 of 142 (66.2%) vs. 83 of 169 (49.1%),
p <0.01 by the chi-square test). Regarding CSF, Table 2 shows
poor performance of VP2 typing for samples found to be
positive in 2010 with the GeneXpert test; this is attributable,
at least in part, to a few strains of E-11 being missed with this
method but not with the VP1 method (data not shown).
In the light of the latter results, the sensitivity of the typing
method was suspected to be related to the viral loads in the
different clinical specimens. As shown in Fig. 2, the median Ct
value obtained with the screening 5′NC methods was lower
for typeable specimens than for untypeable specimens. A
receiver operating characteristic curve could be traced for the
R-gene test; it allowed the determination of threshold values
of 20, 23, 26 and 32 for typeabilities of 90%, 75%, 50% and 10%,
respectively.
Discussion
With reference and clinical strains, the newly described
CODEHOP VP2 method was shown to be more sensitive
and speciﬁc (fewer interfering bands) than the original VP2
method previously described in our laboratory [17]. This
method showed at least the same sensitivity, and even better
sensitivity, than the VP1 reference method [6] on different
strains belonging to the four species of EV, except for the PV-1
vaccine strain.
Following these encouraging results and by analogy with the
VP1 strategy using CODEHOP primers [6], we prospectively
evaluated the capacity of the CODEHOP VP2 method to be
used for EV typing without any culture step on a large panel of
clinical specimens found to be positive with sensitive RT-PCR
assays based on the 5′NC region. Globally, a genotype could
be assigned to 58.0% of the specimens, with a clear relation-
ship between the ability to type and the viral load. The overall
sensitivity of the methods targeting the four A to D species of
human EV on clinical specimens without cell culture ampliﬁ-
cation is not very high (approximately 50%), even when
CODEHOP degenerated primers are used ([23] (this study).
Several studies have reported higher typing performance
either with a panel of specimens containing exclusively EV-B
strains [24,25] or with species B-speciﬁc primers [9,11,13,26–
TABLE 3. Genotypes detected in the 204 clinical specimens
that could be typed with the VP2 method
Genotype
Year
Total2010 2011 2012
CV-A2 0 1 0 1
CV-A4 2 0 3 5
CV-A6 3 6 11 20
CV-A10 3 0 3 6
CV-A16 0 0 1 1
EV-A71 0 0 1 1
CV-B1 0 0 1 1
CV-B2 10 1 0 11
CV-B3 0 1 0 1
CV-B4 0 1 22 23
CV-B5 2 2 10 14
E-2 0 2 0 2
E-4 2 0 0 2
E-5 0 0 1 1
E-6 13 56 0 69
E-7 0 3 2 5
E-9 0 3 6 9
E-11 4 1 1 6
E-16 3 0 0 3
E-17 1 0 0 1
E-18 1 1 2 4
E-25 1 2 4 7
E-30 4 4 0 8
EV-D68 3 0 0 3
Untypeable Typeable
C
t G
en
eX
pe
rt 
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sa
y
Untypeable Typeable
C
t R
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(a)
(b)
40.00
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25.00
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15.00
FIG. 2. Box plots comparing the Ct values obtained with (a) the
GeneXpert test and (b) the R-gene test targeting the 5′NC region in
two groups of samples according to their typeability by use of the VP2
method. The median Ct value obtained was lower for typeable samples
than for untypeable ones (32.20 vs. 33.01, p <0.05 for the GeneXpert
test, and 25.96 vs. 31.74, p <0.001 for the R-gene test, by use of the
Mann–Whitney–Wilcoxon test).
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29]. In the light of these considerations, two strategies could be
proposed for EV typing in human specimens. The ﬁrst would
consist of startingwith amethod covering a large spectrumof EV
types, as shown in this study, and retesting the negative
specimens with species-speciﬁc primers chosen according to
clinical and epidemiological data, whereas the second would
consist of starting with species-speciﬁc primers (notably EV-B
species), and retesting the untypeable specimens with a
CODEHOP method covering the whole range of EV types.
Moreover, from an epidemiological point of view, obtaining an
exhaustive picture of all of the circulating genotypes of EV is not
realistic. However, the typing method must be able to detect
almost uniformly all of the different types of EV.
The results from the present study, notably those shown in
Fig. 2, suggest that the capacity for a specimen to be typed is
related to its viral load. CSF specimens, which are known to
show low viral loads [7,30], were found herein to give a typing
result in c. 50% of the tested specimens; by contrast, 66% of
the other specimens were found to be typeable with the same
strategy. Consequently, the initial viral load observed with the
screening 5′NC technique could be used to determine which
strategy has a higher probability of giving a positive typing
result. In CSF specimens and in peripheral specimens with low
viral loads, the methods using species-speciﬁc primers could be
recommended ﬁrst, whereas the CODEHOP method target-
ing the VP2 region could be preferred on samples with high
viral loads (a threshold of 23 with the R-gene test was shown
to allow the typing of 75% of the samples in this study). In the
case of EV neurological disease, it is suggested to use a
peripheral specimen (throat swab or stools) as well as a CSF
specimen, to increase the chance of typing the causative EV
strain with the VP2 method. Even if it is preferable to use CSF
to ﬁrmly identify the type responsible for a neurological
disease, the use of peripheral specimens has already been
recommended for diagnostic purpose [27,31–33].
In conclusion, the newly described VP2 typing method with
CODEHOP primers was shown to be a good alternative to the
reference method targeting the VP1 region for characterizing
EV strains without cell culture isolation, at least in those
clinical specimens with high viral loads. Large multicentre
studies are needed to evaluate the place of this new typing
method among the different strategies that are emerging with
the increased use of molecular biology in the ﬁeld of EV
epidemiology.
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